Company intelligence / Profile preview

CG Oncology, Inc.

Irvine, California, United Statescgoncology.com ↗

Ownership: Public · CGON
Development stage: Phase 3

Overview

CG Oncology's lead candidate, cretostimogene grenadenorepvec, has shown clinical benefit and has been generally well-tolerated as both a monotherapy and in combination with other therapies in clinical trials for BCG-unresponsive NMIBC. The BOND-003 Phase 3 trial for high-risk BCG-unresponsive NMIBC is fully enrolled, with results accepted for presentation at the Society of Urologic Oncology 25th Annual Meeting. The CORE-001 Phase 2 study of cretostimogene in combination with pembrolizumab showed a 54% complete response rate at the 24-month landmark.

Therapeutic areas: Oncology
Modalities: Oncolytic immunotherapy
Industry: Biotech

Drug pipeline

4 assets

cretostimogene grenadenorepvec

3 more assets in the full pipeline.

Request access →

Partnerships

Collaboration with pembrolizumab (KEYTRUDA)Collaboration with nivolumab (OPDIVO)

Financials

Market cap: $6.4B
Total revenue: $1.2M
Enterprise value: $5.3B

Beyond the preview

Go deeper on CG Oncology, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CG Oncology, Inc..

Explore the full profile